EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall
SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) — EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the achievement of a first CTA